Nuvectis Pharma Key Executives
This section highlights Nuvectis Pharma's key executives, including their titles and compensation details.
Find Contacts at Nuvectis Pharma
(Showing 0 of )
Nuvectis Pharma Earnings
This section highlights Nuvectis Pharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
$9.72
Stock Price
$227.37M
Market Cap
13
Employees
Fort Lee, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Nuvectis Pharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $149.00K | $- | $- |
| Cost of Revenue | $- | $22.90M | $19.23M | $12.89M | $- |
| Gross Profit | $- | $-22.90M | $-19.09M | $-12.89M | $- |
| Gross Profit Ratio | 0.00% | 0.00% | -12808.72% | 0.00% | 0.00% |
| Research and Development Expenses | $12.92M | $15.38M | $13.23M | $9.54M | $- |
| General and Administrative Expenses | $6.93M | $7.50M | $6.01M | $3.35M | $24.00K |
| Selling and Marketing Expenses | $- | $14.00K | $- | $- | $9.98K |
| Selling General and Administrative Expenses | $6.93M | $7.52M | $6.01M | $3.35M | $10.00K |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $19.85M | $22.90M | $19.23M | $12.89M | $10.00K |
| Cost and Expenses | $- | $22.90M | $19.23M | $12.89M | $10.00K |
| Interest Income | $- | $637.00K | $149.00K | $4.00K | $- |
| Interest Expense | $- | $- | $149.00K | $- | $- |
| Depreciation and Amortization | $- | $-1.00M | $-1.20M | $-7.10M | $24.00K |
| EBITDA | $- | $-22.90M | $-19.23M | $-12.89M | $- |
| EBITDA Ratio | 0.00% | 0.00% | -12908.72% | 0.00% | 0.00% |
| Operating Income | $- | $-22.90M | $-19.23M | $-12.89M | $-10.00K |
| Operating Income Ratio | 0.00% | 0.00% | -12908.72% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $- | $637.00K | $149.00K | $4.00K | $14.00K |
| Income Before Tax | $-19.00M | $-22.26M | $-19.09M | $-12.89M | $-10.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | -12808.72% | 0.00% | 0.00% |
| Income Tax Expense | $-19.00M | $- | $-298.00K | $-4.00K | $-24 |
| Net Income | $-19.00M | $-22.26M | $-18.79M | $-12.89M | $-10.00K |
| Net Income Ratio | 0.00% | 0.00% | -12608.72% | 0.00% | 0.00% |
| EPS | $-1.11 | $-1.43 | $-1.48 | $-1.01 | $0.00 |
| EPS Diluted | $-1.11 | $-1.43 | $-1.48 | $-1.01 | $0.00 |
| Weighted Average Shares Outstanding | 17.11M | 15.56M | 12.66M | 12.72M | 12.72M |
| Weighted Average Shares Outstanding Diluted | 17.11M | 15.56M | 12.66M | 12.72M | 12.72M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $-4.10M | $- | $- | $4.10M | $149.00K | $- | $- | $- | $4.00K | $- | $- | $- |
| Cost of Revenue | $- | $4.36M | $4.64M | $4.40M | $10.97M | $6.16M | $5.77M | $- | $- | $- | $3.57M | $2.94M | $- | $- | $- | $- |
| Gross Profit | $- | $-4.36M | $-4.64M | $-4.40M | $-15.07M | $-6.16M | $-5.77M | $4.10M | $149.00K | $- | $-3.57M | $-2.94M | $4.00K | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 367.40% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $4.50M | $2.82M | $2.94M | $2.66M | $4.26M | $4.49M | $4.26M | $2.37M | $4.40M | $4.52M | $2.50M | $1.80M | $1.14M | $4.16M | $4.25M | $- |
| General and Administrative Expenses | $1.95M | $1.54M | $1.70M | $1.74M | $2.60M | $1.67M | $1.51M | $1.73M | $2.38M | $1.42M | $1.07M | $1.14M | $1.12M | $512.00K | $1.69M | $23.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.95M | $1.54M | $1.70M | $1.74M | $2.60M | $1.67M | $1.51M | $1.73M | $2.38M | $1.42M | $1.07M | $1.14M | $1.12M | $512.00K | $1.69M | $23.00K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $6.45M | $4.36M | $4.64M | $4.40M | $6.87M | $6.16M | $5.77M | $4.10M | $6.78M | $5.94M | $3.57M | $2.94M | $2.27M | $4.67M | $5.94M | $23.00K |
| Cost and Expenses | $6.45M | $4.36M | $4.64M | $4.40M | $6.87M | $6.16M | $5.77M | $4.10M | $6.78M | $5.94M | $3.57M | $2.94M | $2.27M | $4.67M | $5.94M | $23.00K |
| Interest Income | $201.00K | $206.00K | $215.00K | $225.00K | $244.00K | $277.00K | $64.00K | $52.00K | $82.00K | $61.00K | $4.00K | $2.00K | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $52.00K | $- | $- | $- | $82.00K | $- | $4.00K | $2.00K | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $- | $- | $43.28K | $-1.00M | $-39.59K | $122.08K | $4.10M | $-1.20M | $- | $86.06K | $-4.00K | $-7.10M | $4.67M | $5.94M | $23.00K |
| EBITDA | $-6.45M | $-4.36M | $-4.64M | $-4.40M | $-6.87M | $-6.16M | $-5.77M | $- | $-6.78M | $-5.94M | $-3.57M | $-2.94M | $-2.27M | $-4.67M | $-5.94M | $-23.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 167.42% | 0.00% | 0.00% | -100.00% | -4548.99% | 0.00% | 0.00% | 0.00% | -56625.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-6.45M | $-4.36M | $-4.64M | $-4.40M | $-6.87M | $-6.16M | $-5.77M | $-4.10M | $-6.78M | $-5.94M | $-3.57M | $-2.94M | $-2.27M | $-4.67M | $-5.94M | $-23.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 167.42% | 0.00% | 0.00% | -100.00% | -4548.99% | 0.00% | 0.00% | 0.00% | -56625.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $201.00K | $206.00K | $215.00K | $225.00K | $244.00K | $277.00K | $64.00K | $52.00K | $82.00K | $61.00K | $4.00K | $2.00K | $4.00K | $- | $- | $- |
| Income Before Tax | $-6.25M | $-4.15M | $-4.43M | $-4.17M | $-6.62M | $-5.88M | $-5.71M | $-4.05M | $-6.70M | $-5.88M | $-3.57M | $-2.94M | $-2.26M | $-4.67M | $-5.94M | $-23.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 161.47% | 0.00% | 0.00% | -98.73% | -4493.96% | 0.00% | 0.00% | 0.00% | -56525.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $-43.28K | $1.00K | $6.20M | $5.65M | $-52.00K | $-164.00K | $- | $-8.00K | $-4.00K | $-4.00K | $-4.67M | $-5.94M | $-23.00K |
| Net Income | $-6.25M | $-4.15M | $-4.43M | $-4.17M | $-6.62M | $-5.88M | $-5.71M | $-4.00M | $-6.53M | $-5.88M | $-3.56M | $-2.94M | $-2.26M | $-4.67M | $-5.94M | $-23.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 161.47% | 0.00% | 0.00% | -97.46% | -4383.89% | 0.00% | 0.00% | 0.00% | -56525.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.37 | $-0.24 | $-0.26 | $-0.25 | $-0.38 | $-0.37 | $-0.38 | $-0.27 | $-0.45 | $-0.42 | $-0.28 | $-0.32 | $-0.18 | $-0.39 | $-0.47 | $0.00 |
| EPS Diluted | $-0.37 | $-0.24 | $-0.26 | $-0.25 | $-0.38 | $-0.37 | $-0.38 | $-0.27 | $-0.45 | $-0.42 | $-0.28 | $-0.32 | $-0.18 | $-0.39 | $-0.47 | $0.00 |
| Weighted Average Shares Outstanding | 17.11M | 17.23M | 16.90M | 16.56M | 17.42M | 16.10M | 15.18M | 14.72M | 14.64M | 14.05M | 12.72M | 9.16M | 12.72M | 11.82M | 12.72M | 12.72M |
| Weighted Average Shares Outstanding Diluted | 17.11M | 17.23M | 16.90M | 16.56M | 17.42M | 16.10M | 15.18M | 14.72M | 14.64M | 14.05M | 12.72M | 9.16M | 12.72M | 11.82M | 12.72M | 12.72M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $18.53M | $19.13M | $19.99M | $5.74M | $- |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $18.53M | $19.13M | $19.99M | $5.74M | $- |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $74.00K | $59.00K | $412.00K | $91.00K | $- |
| Total Current Assets | $18.61M | $19.18M | $20.41M | $5.83M | $- |
| Property Plant Equipment Net | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $824.00K | $- |
| Total Non-Current Assets | $- | $- | $- | $824.00K | $- |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $18.61M | $19.18M | $20.41M | $6.66M | $- |
| Account Payables | $2.50M | $2.77M | $2.91M | $1.06M | $10.00K |
| Short Term Debt | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $6.40M | $4.21M | $3.28M | $1.36M | $- |
| Total Current Liabilities | $8.89M | $6.98M | $6.19M | $2.42M | $10.00K |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $2.91M | $15.25M | $- |
| Other Liabilities | $- | $- | $-2.91M | $- | $- |
| Total Liabilities | $8.89M | $6.98M | $6.19M | $17.66M | $10.00K |
| Preferred Stock | $- | $- | $20.41M | $15.25M | $- |
| Common Stock | $- | $- | $14.75B | $- | $- |
| Retained Earnings | $-73.25M | $-54.24M | $-31.98M | $-12.90M | $-10.00K |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-14.75B | $0 | $- |
| Other Total Stockholders Equity | $82.96M | $66.45M | $46.20M | $1.89M | $- |
| Total Stockholders Equity | $9.71M | $12.20M | $14.22M | $-11.01M | $-10.00K |
| Total Equity | $9.71M | $12.20M | $14.22M | $-11.01M | $-10.00K |
| Total Liabilities and Stockholders Equity | $18.61M | $19.18M | $20.41M | $6.66M | $- |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $18.61M | $19.18M | $20.41M | $6.66M | $- |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $- | $- | $- | $- | $- |
| Net Debt | $-18.53M | $-19.13M | $-19.99M | $-5.74M | $- |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $18.53M | $17.17M | $18.12M | $19.46M | $19.13M | $22.06M | $24.60M | $15.47M | $19.99M | $23.64M | $13.57M | $16.69M | $5.74M | $6.81M | $7.21M | $- |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $18.53M | $17.17M | $18.12M | $19.46M | $19.13M | $22.06M | $24.60M | $15.47M | $19.99M | $23.64M | $13.57M | $16.69M | $5.74M | $6.81M | $7.21M | $- |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $74.00K | $138.00K | $182.00K | $250.00K | $59.00K | $203.00K | $341.00K | $740.00K | $412.00K | $1.23M | $666.00K | $925.00K | $91.00K | $- | $- | $- |
| Total Current Assets | $18.61M | $17.31M | $18.30M | $19.71M | $19.18M | $22.26M | $24.94M | $16.21M | $20.41M | $24.87M | $14.24M | $17.62M | $5.83M | $6.81M | $7.21M | $- |
| Property Plant Equipment Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $824.00K | $- | $- | $- |
| Total Non-Current Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $824.00K | $- | $- | $- |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $18.61M | $17.31M | $18.30M | $19.71M | $19.18M | $22.26M | $24.94M | $16.21M | $20.41M | $24.87M | $14.24M | $17.62M | $6.66M | $6.81M | $7.21M | $- |
| Account Payables | $2.50M | $2.26M | $1.85M | $1.76M | $2.77M | $3.49M | $1.80M | $2.10M | $2.91M | $2.25M | $1.43M | $1.35M | $1.06M | $495.00K | $389.00K | $33.00K |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $6.40M | $4.05M | $3.92M | $3.93M | $4.21M | $2.08M | $2.81M | $1.84M | $3.28M | $2.24M | $1.30M | $1.71M | $1.36M | $- | $- | $- |
| Total Current Liabilities | $8.89M | $6.32M | $5.77M | $5.69M | $6.98M | $5.58M | $4.61M | $3.93M | $6.19M | $4.49M | $2.74M | $3.06M | $2.42M | $495.00K | $389.00K | $33.00K |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $15.25M | $11.22M | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $2.10M | $2.91M | $- | $1.43M | $1.35M | $15.25M | $15.25M | $11.22M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $-2.10M | $-2.91M | $- | $-1.43M | $-1.35M | $- | $- | $- | $- |
| Total Liabilities | $8.89M | $6.32M | $5.77M | $5.69M | $6.98M | $5.58M | $4.61M | $3.93M | $6.19M | $4.49M | $2.74M | $3.06M | $17.66M | $15.74M | $11.61M | $33.00K |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $14.24M | $17.62M | $15.25M | $15.25M | $11.22M | $- |
| Common Stock | $- | $- | $18.65B | $- | $17.77B | $17.33B | $17.23B | $- | $- | $- | $- | $0 | $- | $- | $- | $- |
| Retained Earnings | $-73.25M | $-67.00M | $-62.84M | $-58.42M | $-54.24M | $-47.62M | $-41.74M | $-36.03M | $-31.98M | $-25.29M | $-19.41M | $-15.84M | $-12.90M | $-10.64M | $-5.97M | $-33.00K |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $0 | $- | $-0 | $0 | $-0 | $- | $- |
| Other Total Stockholders Equity | $82.96M | $77.99M | $75.37M | $72.44M | $66.45M | $64.31M | $62.07M | $48.31M | $46.20M | $45.66M | $30.91M | $30.40M | $1.89M | $-13.54M | $-9.65M | $- |
| Total Stockholders Equity | $9.71M | $10.99M | $12.53M | $14.02M | $12.20M | $16.69M | $20.33M | $12.27M | $14.22M | $20.37M | $11.50M | $14.56M | $-11.01M | $-8.93M | $-4.40M | $-33.00K |
| Total Equity | $9.71M | $10.99M | $12.53M | $14.02M | $12.20M | $16.69M | $20.33M | $12.27M | $14.22M | $20.37M | $11.50M | $14.56M | $-11.01M | $-8.93M | $-4.40M | $-33.00K |
| Total Liabilities and Stockholders Equity | $18.61M | $17.31M | $18.30M | $19.71M | $19.18M | $22.26M | $24.94M | $16.21M | $20.41M | $24.87M | $14.24M | $17.62M | $6.66M | $6.81M | $7.21M | $- |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $18.61M | $17.31M | $18.30M | $19.71M | $19.18M | $22.26M | $24.94M | $16.21M | $20.41M | $24.87M | $14.24M | $17.62M | $6.66M | $6.81M | $7.21M | $- |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-18.53M | $-17.17M | $-18.12M | $-19.46M | $-19.13M | $-22.06M | $-24.60M | $-15.47M | $-19.99M | $-23.64M | $-13.57M | $-16.69M | $-5.74M | $-6.81M | $-7.21M | $- |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-19.00M | $-22.26M | $-19.09M | $-12.89M | $-24.00K |
| Depreciation and Amortization | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $4.86M | $4.71M | $1.71M | $1.89M | $- |
| Change in Working Capital | $1.90M | $1.74M | $3.82M | $1.49M | $10.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-273.00K | $-139.00K | $4.14M | $1.58M | $- |
| Other Working Capital | $2.17M | $1.88M | $-321.00K | $-91.00K | $10.00K |
| Other Non Cash Items | $- | $-139.00K | $-2.43M | $307.00K | $24.00K |
| Net Cash Provided by Operating Activities | $-12.25M | $-15.95M | $-13.56M | $-9.50M | $24.00K |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $12.04M | $5.29M | $31.88M | $15.25M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-382.00K | $9.80M | $-4.07M | $15.25M | $- |
| Net Cash Used Provided by Financing Activities | $11.65M | $15.09M | $27.81M | $15.25M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-593.00K | $-867.00K | $14.25M | $5.74M | $24.00K |
| Cash at End of Period | $18.53M | $19.13M | $19.99M | $5.74M | $24.00K |
| Cash at Beginning of Period | $19.13M | $19.99M | $5.74M | $- | $- |
| Operating Cash Flow | $-12.25M | $-15.95M | $-13.56M | $-9.50M | $24.00K |
| Capital Expenditure | $- | $- | $- | $- | $- |
| Free Cash Flow | $-12.25M | $-15.95M | $-13.56M | $-9.50M | $24.00K |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-6.25M | $-4.15M | $-4.43M | $-4.17M | $-6.62M | $-5.88M | $-5.71M | $-4.05M | $-6.70M | $-5.88M | $-3.57M | $-2.94M | $-2.26M | $-4.67M | $-5.94M | $-23.00K |
| Depreciation and Amortization | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.14M | $-2.58M | $1.26M | $1.30M | $1.22M | $1.13M | $950.00K | $1.40M | $482.00K | $559.00K | $510.00K | $156.00K | $185.00K | $136.00K | $1.57M | $- |
| Change in Working Capital | $2.64M | $1.34M | $146.00K | $-1.48M | $1.55M | $1.50M | $675.00K | $-2.13M | $2.70M | $894.00K | $516.00K | $-289.00K | $1.01M | $106.00K | $356.00K | $23.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $237.00K | $415.00K | $87.00K | $-1.01M | $21.00K | $- | $-293.00K | $-814.00K | $- | $- | $- | $542.00K | $1.48M | $106.00K | $- | $- |
| Other Working Capital | $2.40M | $922.00K | $59.00K | $-471.00K | $1.53M | $1.50M | $675.00K | $-2.13M | $2.70M | $-560 | $516.00K | $-831.00K | $-470.00K | $106.00K | $356.00K | $- |
| Other Non Cash Items | $- | $3.00M | $1.18M | $2.31M | $1.20M | $1.13M | $950.00K | $1.40M | $482.00K | $1.51K | $510.00K | $156.00K | $185.00K | $136.00K | $1.57M | $23.00K |
| Net Cash Provided by Operating Activities | $-2.46M | $-2.40M | $-3.02M | $-4.36M | $-3.85M | $-3.24M | $-4.08M | $-4.78M | $-3.52M | $-4.42M | $-2.54M | $-3.08M | $-1.07M | $-4.43M | $-4.01M | $- |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $3.95M | $1.51M | $1.73M | $4.85M | $901.00K | $1.13M | $3.26M | $252.00K | $-131.00K | $15.88M | $-578.00K | $16.00M | $- | $4.02M | $11.22M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-124.00K | $-50.00K | $-55.00K | $-153.00K | $16.00K | $-423.00K | $9.95M | $252.00K | $-131.00K | $-1.39M | $-578.00K | $-1.97M | $- | $4.02M | $11.22M | $- |
| Net Cash Used Provided by Financing Activities | $3.83M | $1.46M | $1.67M | $4.70M | $917.00K | $703.00K | $13.21M | $252.00K | $-131.00K | $14.49M | $-578.00K | $14.03M | $- | $4.02M | $11.22M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.36M | $-947.00K | $-1.35M | $338.00K | $-2.93M | $-2.54M | $9.13M | $-4.53M | $-3.65M | $10.07M | $-3.12M | $10.95M | $-1.07M | $-405.00K | $7.21M | $- |
| Cash at End of Period | $18.53M | $17.17M | $18.12M | $19.46M | $19.13M | $22.06M | $24.60M | $15.47M | $19.99M | $23.64M | $13.57M | $16.69M | $5.74M | $6.81M | $7.21M | $- |
| Cash at Beginning of Period | $17.17M | $18.12M | $19.46M | $19.13M | $22.06M | $24.60M | $15.47M | $19.99M | $23.64M | $13.57M | $16.69M | $5.74M | $6.81M | $7.21M | $- | $- |
| Operating Cash Flow | $-2.46M | $-2.40M | $-3.02M | $-4.36M | $-3.85M | $-3.24M | $-4.08M | $-4.78M | $-3.52M | $-4.42M | $-2.54M | $-3.08M | $-1.07M | $-4.43M | $-4.01M | $- |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-2.46M | $-2.40M | $-3.02M | $-4.36M | $-3.85M | $-3.24M | $-4.08M | $-4.78M | $-3.52M | $-4.42M | $-2.54M | $-3.08M | $-1.07M | $-4.43M | $-4.01M | $- |
Nuvectis Pharma Dividends
Explore Nuvectis Pharma's dividend history, including dividend yield, payout ratio, and historical payments.
Nuvectis Pharma News
Read the latest news about Nuvectis Pharma, including recent articles, headlines, and updates.
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California.
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
NEW YORK--(BUSINESS WIRE)---- $NVCT #Pharma--Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (Nasdaq: NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need. Lucid's report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safe.
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter's option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback
The company's stock dropped due to disappointing phase 1b results for NXP800 in ARID1a-mutated ovarian cancer, but higher dosing may improve outcomes in Q2 2025. The company is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting toxicities. The global ovarian cancer market is expected to reach $11.18 billion by 2029.
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price of $5.00 per share, with expected gross proceeds to Nuvectis of $13.5 million. Nuvectis has also granted the underwriter a 30-day option to purchase up to 405,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 6, 2025, subject to customary closing conditions.
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Nuvectis Pharma (NVCT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma, Inc. NVCT stock is trading lower after the company reported data from the Phase 1b study evaluating NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer.
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
Nuvectis Pharma (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
The consensus price target hints at a 169.9% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2024 and provided an update on recent business progress.
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial.
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration (“FDA”) for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2024 and provided an update on recent business progress.
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2024 and provided an update on recent business progress.
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTM Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, California. Presentation details are below:
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious Condition of Unmet Medical Need with a Median Life Expectancy of Approximately One Year Fort Lee, NJ, March 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration (“FDA”).
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
FORT LEE, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the fiscal year 2023 and provided an update on recent business progress.
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
FORT LEE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter 2023 and provided an update on recent business progress.
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for NVCT.